The company develops and commercializes proprietary molecular-based diagnostic, prognostic, and predictive tests that provide physicians with actionable information to help guide cancer treatment, and is a leader in the development of evidence-based biomarkers to address unmet medical needs. Biotheranostics offers testing services through its CLIA-certified, CAP-accredited laboratory that is directly licensed or otherwise authorized to perform testing in all 50 states. Recently, Biotheranostics was acquired by Hologic, an innovative medical technology company that is passionate about advancing women's health and well-being.